LCC-CNRS, Université de Toulouse, CNRS, UPS, 205 route de Narbonne, 31077, Toulouse, France.
Université de Limoges, UMR INSERM 1094, Neuroépidémiologie Tropicale, Faculté de Pharmacie, 2 rue du Dr Marcland, 87025, Limoges, France.
ChemMedChem. 2018 Oct 22;13(20):2217-2228. doi: 10.1002/cmdc.201800456. Epub 2018 Sep 17.
An antikinetoplastid pharmacomodulation study at position 3 of the recently described hit molecule 3-bromo-8-nitroquinolin-2(1H)-one was conducted. Twenty-four derivatives were synthesised using the Suzuki-Miyaura cross-coupling reaction and evaluated in vitro on both Leishmania infantum axenic amastigotes and Trypanosoma brucei brucei trypomastigotes. Introduction of a para-carboxyphenyl group at position 3 of the scaffold led to the selective antitrypanosomal hit molecule 3-(4-carboxyphenyl)-8-nitroquinolin-2(1H)-one (21) with a lower reduction potential (-0.56 V) than the initial hit (-0.45 V). Compound 21 displays micromolar antitrypanosomal activity (IC =1.5 μm) and low cytotoxicity on the human HepG2 cell line (CC =120 μm), having a higher selectivity index (SI=80) than the reference drug eflornithine. Contrary to results previously obtained in this series, hit compound 21 is inactive toward L. infantum and is not efficiently bioactivated by T. brucei brucei type I nitroreductase, which suggests the existence of an alternative mechanism of action.
对最近描述的命中分子 3-溴-8-硝基喹啉-2(1H)-酮在位置 3 进行了抗动力原生质体药物修饰研究。使用 Suzuki-Miyaura 交叉偶联反应合成了 24 种衍生物,并在体外对利什曼原虫无鞭毛体和布氏锥虫布氏锥虫鞭毛体进行了评估。在支架的 3 位引入对羧苯基,得到了选择性抗锥虫的命中分子 3-(4-羧苯基)-8-硝基喹啉-2(1H)-酮(21),其还原电位(-0.56 V)低于初始命中分子(-0.45 V)。化合物 21 对人体 HepG2 细胞系具有微摩尔抗锥虫活性(IC =1.5 μm)和低细胞毒性(CC =120 μm),其选择性指数(SI=80)高于参考药物依氟鸟氨酸。与该系列先前获得的结果相反,命中化合物 21对 L. infantum 无效,并且不能被 T. brucei brucei 型 I 硝基还原酶有效生物转化,这表明存在替代作用机制。